(Q33544591)

27 July 2017

1 reference

title

Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance (English)

1 reference

27 July 2017

Lode H

1

1 reference

27 July 2017

Vogel F

series ordinal

2

1 reference

27 July 2017

Elies W

series ordinal

3

1 reference

27 July 2017

publication date

1 January 1999

1 reference

27 July 2017

published in

Clinical Therapeutics

1 reference

27 July 2017

volume

21

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

61-74; discussion 1-2

1 reference

Grepafloxacin--focus on respiratory infections

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Safety profile of grepafloxacin compared with other fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Safety and tolerability of fluoroquinolones.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

The activity of grepafloxacin against respiratory pathogens in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Antibacterial activity of grepafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Activity of grepafloxacin against respiratory isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Bullous photodermatosis after lomefloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

Theophylline and warfarin interaction studies with grepafloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988268-5

7 January 2021

10.1016/S0149-2918(00)88268-5

Identifiers

DOI

1 reference

27 July 2017

1 reference